echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > Crestor and zetia patents expire and the market of cholesterol lowering drugs is affected

    Crestor and zetia patents expire and the market of cholesterol lowering drugs is affected

    • Last Update: 2016-01-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Source: pharmacogeography 2016-01-27 there are many stories at the end of 2015, cheering the great achievements of the biopharmaceutical industry in drug innovation (FDA approved new drugs) However, all drug market monopolies are limited Although a number of important new drugs came out in 2015, many drugs will lose patent protection in 2016, including those for AIDS, mental illness and hypertension The most striking are two kinds of LDL-C lowering drugs: AstraZeneca's statin drug creator (rosuvastatin calcium tablets, rosuvastatin calcium tablets) and Merck's cholesterol absorption inhibitor zetia (ezetimibe tablets, ezetimibe tablets) The expired patents are usre37314 (pyrimidine derivatives) and usre37721, usre42461 (hydroxy substituted azetidine compounds useful as hybrid agents) Whenever a drug loses its patent protection, its price will drop sharply when it encounters generic competition It is expected that Crestor and zetia's sales revenue in the United States will decline by 90% in about 12 months However, the presence of Crestor and zetia's generic drugs has other implications, both commercial and medical Merck's cholesterol lowering drug Vytorin, with sales of more than $1 billion, is actually a combination of ezeimibo and simvastatin It can reduce LDL-C through the complementary action of two components, which provides a simple method for doctors to treat patients with heart disease However, medical insurance payment institutions do not really care about convenience Their main concern is to control costs Last year, zetia's 30 day prescription cost was about $300, equivalent to Vytorin's 30 day fee However, 30 days later, the cost of generic ezeki will be less than $10 In this way, the medical insurance agency will refuse to pay for Vytorin, and require patients to take two imitations of ezema cloth and simvastatin respectively It does cause inconvenience to patients and doctors However, this will save health insurance institutions millions of dollars (every year) However, the introduction of imitation products of ezemeb and rosuvastatin will have other effects Because of side effects such as muscle pain, many people can't tolerate statins The inability to tolerate statins actually drives companies to look for new incentives to reduce LDL-C But the road has become more difficult Interestingly, the problem of statins tolerance in some patients can be solved by stopping treatment for a short period of time and then restarting Therefore, medical insurance institutions will promote the use of multiple statins to make the diagnosis of intolerable statins If there is a problem with all statins, we will encourage the trial of ezymab, because the imitated products of ezymab will be as cheap as statins Therefore, it will reduce the number of heart disease patients with "intolerant statins" targeted by etc-1002, a new LDL-C drug that esperion is actively developing According to the information released in August 2015, etc-1002 has a common advantage over pcsk-9 inhibitors in phase II study But the most eye-catching new drugs for LDL-C reduction are pcsk-9 inhibitors, praluent (Sanofi / regenerant) and repatha (Amgen) The ability of these drugs to reduce LDL-C is beyond the reach of statins alone In theory, rosuvastatin and the imitation of ezeimab will not have a significant impact on the sales of pcsk-9 drugs However, so far, the developers of praluent (alirocumab) and repatha (evolocumab) have failed to prove the survival benefits of patients with heart disease whose LDL-C level is 45 mg / dL or 70 mg / L, and it will take time (in the next two years) to obtain relevant data Pcsk-9 inhibitors are expensive, costing more than $14000 per patient per year Medicare is bound to require heart patients and their physicians to try a variety of alternatives before using expensive pcsk-9 inhibitors, such as rosuvastatin and ezemeb If the LDL-C level of patients can be reduced to less than 70 mg / dl with a combination of drugs, and the cost is less than $1 per day, the combination will be used for a long time There is no doubt that the loss of patent protection for Crestor and zetia will affect the bottom line of AstraZeneca and Merck However, their imitation products should have an impact on doctors' prescribing habits and even new drugs that have not yet been approved for marketing Nowadays, medical cost is the first problem to be considered, especially in the face of expensive new drugs, the use of generic drugs is an important lever to achieve cost reduction.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.